Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States

This multicenter, prospective study reports excellent procedural outcomes, acceptable 1-year mortality rates, and a significant improvement in quality of life for patients undergoing transseptal MViV in the contemporary era. Patients in the low-risk and intermediate-risk STS score categories had significantly better outcomes compared with those in the high-risk category. MViV is a reasonable therapy for the majority of patients with degenerated bioprosthetic mitral valves, who are anatomical candidates.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2024-08-05
DOI
https://doi.org/10.1161/circulationaha.124.068847
Citations
7
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
2.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States

Amar Krishnaswamy, Susheel Kodali, Colin M. Barker, Kashish Goel et al.
7 citations
Circulation
Cardiac Valve Diseases and Treatments
2.81
article

Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States

Amar Krishnaswamy, Susheel Kodali, Colin M. Barker, Kashish Goel, Raj Makkar, Abhijeet Dhoble, Mayra Guerrero, Charanjit S. Rihal, Amr E. Abbas, Brian Whisenant, Samir Kapadia, Pradeep Yadav, Ke Xu, Ashish S. Shah
article en
7 citations

Abstract

This multicenter, prospective study reports excellent procedural outcomes, acceptable 1-year mortality rates, and a significant improvement in quality of life for patients undergoing transseptal MViV in the contemporary era. Patients in the low-risk and intermediate-risk STS score categories had significantly better outcomes compared with those in the high-risk category. MViV is a reasonable therapy for the majority of patients with degenerated bioprosthetic mitral valves, who are anatomical candidates.

CirculationVol. 150(19)
Cedars-Sinai Medical Center (US), Memorial Hermann (US), Cleveland Clinic (US), Mayo Clinic (US), Columbia University Irving Medical Center (US), Piedmont Atlanta Hospital (US), Intermountain Medical Center (US), Mayo Clinic in Arizona (US), Beaumont Hospital, Royal Oak (US), Mayo Clinic in Florida (US), Edwards Lifesciences (United States) (US), Vanderbilt University Medical Center (US)
Good health and well-being
Openalex Percentile: Top 8%
Cardiac Valve Diseases and Treatments
2.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.